Know Cancer

forgot password

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Phase 2
18 Years
Open (Enrolling)
Locally Advanced HER2-Negative Breast Cancer

Thank you

Trial Information

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Inclusion Criteria:

1. Histologically confirmed invasive adenocarcinoma of the breast.

2. Primary palpable disease confined to the breast and axilla on physical examination
(clinical Stage II or III disease). For patients without clinically suspicious
axillary adenopathy, the primary must be >2 cm in diameter by physical examination or
imaging studies (clinical T2-3, N0-2, M0). For patients with clinically suspicious
axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2,
M0). Patients who have had axillary node dissection and have pN3a (i.e. ≥10 involved
axillary nodes) are also eligible.

3. Patients entering the trial after undergoing an axillary node dissection will be
eligible if they meet other entry criteria.

4. Estrogen receptor (ER) and progesterone receptor (PR) status in the primary tumor
known or pending at the time of study registration.

5. Resolution of all acute effects of surgical procedures to ≤ grade 1. For patients
who had or will have, a sentinel node and/or axillary node dissection, completion at
least 1 week prior to the initiation of study treatment with a well-healed wound is

6. Bilateral, synchronous breast cancer is allowed if both primary tumors are
HER2-negative and at least one meets the specified qualifying tumor or nodal
inclusion criteria.

7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.

8. Patients entering this study must be willing to provide release of tumor tissue
collected at baseline during a diagnostic procedure if available, and at the time of
future surgical procedure(s) for correlative testing. If tissue is not available,
the patient will still be eligible for enrollment to the study.

9. No evidence of metastatic disease, as documented by complete staging workup ≤8 weeks
prior to initiation of study treatment.

10. No prior treatment for this breast cancer with the exception of criterion #3.

11. HER2-negative tumor status defined as:

- Immunohistochemical (IHC) 0-1+ or

- IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence in situ hybridization) or SISH
(Silver in situ hybridization) negative (defined by ratio <2.2)

12. Adequate hematologic function defined as:

- Absolute neutrophil count (ANC) ≥1500/μL

- Hemoglobin (Hgb) ≥10 g/dL

- Platelets ≥100,000/uL

13. Adequate liver function defined as:

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x the
upper limit of normal (ULN)

- Total bilirubin ≤ the institutional ULN

14. Adequate renal function defined as:

- Serum creatinine ≤1.5 mg/dL x ULN OR calculated creatinine clearance ≥50 mL/min
by the Cockcroft-Gault method:

GRF =(140-age) x (weight/kg) x (0.85 if female) (72 x serum creatinine mg/dL)

15. Other laboratory testing:

- Serum magnesium ≥ the institutional lower limit of normal (LLN)

- Serum potassium ≥the institutional LLN

16. Female and ≥18 years of age.

17. Negative serum pregnancy test within <7 days prior to initial trial treatment.

18. Female patients who are not of child-bearing potential, and female patients of
child-bearing potential who agree to use adequate contraceptive measures that are
approved by their study physician while receiving study treatment and continuing for
3 weeks after the last dose of study drug treatment, who are not breastfeeding, and
who have a negative serum pregnancy test prior to start of dosing.

19. Willingness and ability to comply with trial and follow-up procedures.

20. Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

1. Clinical T4 lesions, including inflammatory breast cancer. Clinical N3 involvement
(e.g., ipsilateral, infraclavicular, supraclavicular, and internal mammary nodes).

2. Peripheral neuropathy (motor or sensory) > grade 1 according to Common Terminology
Criteria for Adverse Events version 4.0 (CTCAE v4.0).

3. Patient has received radiotherapy for treatment of previous cancer that included ≥30%
of major bone marrow containing areas (e.g., pelvis, lumbar, spine).

4. Known or suspected allergy or hypersensitivity to any of the study drugs (i.e.,
eribulin, cyclophosphamide, docetaxel) or known hypersensitivity to polysorbate 80.

5. Patients with acute or chronic liver or renal disease or pancreatitis.

6. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis
C (HCV).

7. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal
agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator
(SERM). Patients must have discontinued use of such agents prior to beginning study
treatment. However, use of GNRH agonists for the purpose of fertility preservation
or suppression of heavy menses is permitted (see Section 5.4.1).

8. Patient has any of the following cardiac diseases currently or within the last 6

- Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated
acquisition (MUGA) scan or echocardiogram (ECHO)

- Heart rate-corrected QT interval (QTc) > 480 ms on screening electrocardiogram
(ECG) (using Bazett's formula)

- Unstable angina pectoris

- Congestive heart failure (New York Heart Association [NYHA] ≥ Grade 2

- Acute myocardial infarction

- Conduction abnormality not controlled with pacemaker or medication

- Significant ventricular or supraventricular arrhythmias (Patients with chronic
rate-controlled atrial fibrillation in the absence of other cardiac
abnormalities are eligible).

- Valvular disease with significant compromise in cardiac function

9. Chronic use of drugs that cause QTc prolongation. Patients must discontinue use of
these drugs 7 days prior to the start of study treatment.

10. Presence of other active cancers, or history of treatment for invasive cancer ≤5
years. Patients with stage I cancer who have received definitive local treatment at
least 3 years previously, and are considered unlikely to recur are eligible. All
patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible,
as are patients with history of non-melanoma skin cancer.

11. Patients may not receive any other investigational or anti-cancer treatments while
participating in this trial.

12. Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol.

13. Inability or unwillingness to comply with study and/or follow-up procedures outlined
in the protocol.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The pCR rate of 6 cycles of neoadjuvant patients treated with ErC and TC

Outcome Time Frame:

18 weeks

Safety Issue:


Principal Investigator

Denise A Yardley, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Institutional Review Board

Study ID:




Start Date:

June 2012

Completion Date:

April 2014

Related Keywords:

  • Locally Advanced HER2-negative Breast Cancer
  • Breast Neoplasms



Northeast Georgia Medical CenterGainesville, Georgia  30501
Research Medical CenterKansas City, Missouri  64132
South Carolina Oncology AssociatesColumbia, South Carolina  29201
Virginia Cancer InstituteRichmond, Virginia  23230
The Center for Cancer and Blood DisordersFort Worth, Texas  76104
Center for Cancer and Blood DisordersBethesda, Maryland  20817
Mercy HospitalPortland, Maine  04101
Tennessee OncologyNashville, Tennessee  37203
Grand Rapids Oncology ProgramGrand Rapids, Michigan  49503
Oncology Hematology Care, IncCincinnati, Ohio  45242
Memorial Cancer InstitutePembroke Pines, Florida  33028
Nebraska Methodist Cancer CenterOmaha, Nebraska  68114
Florida Cancer Specialists SouthFt. Myers, Florida  33916
Florida Cancer Specialists NorthFt. Myers, Florida  33916